Now showing items 1-20 of 103

    • 18F-FDG PET/CT Optimizes Treatment in Staphylococcus Aureus Bacteremia and Is Associated with Reduced Mortality. 

      Berrevoets, MAH; Kouijzer, IJE; Aarntzen, EHJG; Janssen, MJR; De Geus-Oei, L-F; Wertheim, HFL; Kullberg, B-J; Oever, JT; Oyen, WJG; Bleeker-Rovers, CP (2017-09)
      Metastatic infection is an important complication of Staphylococcus aureus bacteremia (SAB). Early diagnosis of metastatic infection is crucial, because specific treatment is required. However, metastatic infection can be ...
    • Abscopal effect of radiotherapy in a patient with metastatic diffuse-type giant cell tumor. 

      Desar, IME; Braam, PM; Kaal, SEJ; Gerritsen, WR; Oyen, WJG; van der Graaf, WTA (2016-12)
    • Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 'CREATE'. 

      Schöffski, P; Wozniak, A; Stacchiotti, S; Rutkowski, P; Blay, J-Y; Lindner, LH; Strauss, SJ; Anthoney, A; Duffaud, F; Richter, S; Grünwald, V; Leahy, MG; Reichardt, P; Sufliarsky, J; van der Graaf, WT; Sciot, R; Debiec-Rychter, M; van Cann, T; Marréaud, S; Lia, M; Raveloarivahy, T; Collette, L; Bauer, S (2017-12-01)
      Background: Clear-cell sarcoma (CCSA) is an orphan malignancy, characterized by a specific t(12;22) translocation, leading to rearrangement of the EWSR1 gene and overexpression of MET. We prospectively investigated the ...
    • Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma. 

      Long, GV; Hauschild, A; Santinami, M; Atkinson, V; Mandalà, M; Chiarion-Sileni, V; Larkin, J; Nyakas, M; Dutriaux, C; Haydon, A; Robert, C; Mortier, L; Schachter, J; Schadendorf, D; Lesimple, T; Plummer, R; Ji, R; Zhang, P; Mookerjee, B; Legos, J; Kefford, R; Dummer, R; Kirkwood, JM (2017-11-09)
      BACKGROUND: Combination therapy with the BRAF inhibitor dabrafenib plus the MEK inhibitor trametinib improved survival in patients with advanced melanoma with BRAF V600 mutations. We sought to determine whether adjuvant ...
    • Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. 

      Weber, J; Mandala, M; Del Vecchio, M; Gogas, HJ; Arance, AM; Cowey, CL; Dalle, S; Schenker, M; Chiarion-Sileni, V; Marquez-Rodas, I; Grob, J-J; Butler, MO; Middleton, MR; Maio, M; Atkinson, V; Queirolo, P; Gonzalez, R; Kudchadkar, RR; Smylie, M; Meyer, N; Mortier, L; Atkins, MB; Long, GV; Bhatia, S; Lebbé, C; Rutkowski, P; Yokota, K; Yamazaki, N; Kim, TM; de Pril, V; Sabater, J; Qureshi, A; Larkin, J; Ascierto, PA; CheckMate 238 Collaborators (2017-11-09)
      BACKGROUND: Nivolumab and ipilimumab are immune checkpoint inhibitors that have been approved for the treatment of advanced melanoma. In the United States, ipilimumab has also been approved as adjuvant therapy for melanoma ...
    • Adolescent and young adult (AYA) lymphoma survivors report lower health-related quality of life compared to a normative population: results from the PROFILES registry. 

      Husson, O; Prins, JB; Kaal, SEJ; Oerlemans, S; Stevens, WB; Zebrack, B; van der Graaf, WTA; van de Poll-Franse, LV (2017-02)
      BACKGROUND: Trying to simultaneously achieve developmental milestones and cope with a life-threatening disease may place adolescents and young adults (AYAs) at risk for impaired health-related quality of life (HRQoL) later ...
    • Age does not influence efficacy of ramucirumab in advanced gastric cancer: Subgroup analyses of REGARD and RAINBOW. 

      Muro, K; Cho, JY; Bodoky, G; Goswami, C; Chao, Y; Dos Santos, LV; Shimada, Y; Topuzov, E; Van Cutsem, E; Tabernero, J; Zalcberg, J; Chau, I; Cascinu, S; Cheng, R; Hsu, Y; Emig, M; Orlando, M; Fuchs, C (2018-04)
      BACKGROUND AND AIM: REGARD and RAINBOW were global, phase 3, randomized, double-blind trials of second-line ramucirumab for metastatic gastric or gastroesophageal junction adenocarcinoma. Exploratory subgroup analyses were ...
    • Age-related sarcoma patient experience: results from a national survey in England. 

      Younger, E; Husson, O; Bennister, L; Whelan, J; Wilson, R; Roast, A; Jones, RL; van der Graaf, WT (2018-10-17)
      BACKGROUND: Sarcomas are rare, heterogeneous tumours affecting patients of any age. Previous surveys describe that sarcoma patients report a significantly worse experience than those with common cancers. Consequently, ...
    • Age-specific genome-wide association study in glioblastoma identifies increased proportion of 'lower grade glioma'-like features associated with younger age. 

      Ostrom, QT; Kinnersley, B; Armstrong, G; Rice, T; Chen, Y; Wiencke, JK; McCoy, LS; Hansen, HM; Amos, CI; Bernstein, JL; Claus, EB; Eckel-Passow, JE; Il'yasova, D; Johansen, C; Lachance, DH; Lai, RK; Merrell, RT; Olson, SH; Sadetzki, S; Schildkraut, JM; Shete, S; Rubin, JB; Andersson, U; Rajaraman, P; Chanock, SJ; Linet, MS; Wang, Z; Yeager, M; GliomaScan consortium; Houlston, RS; Jenkins, RB; Wrensch, MR; Melin, B; Bondy, ML; Barnholtz-Sloan, JS (2018-11-15)
      Glioblastoma (GBM) is the most common malignant brain tumor in the United States. Incidence of GBM increases with age, and younger age-at-diagnosis is significantly associated with improved prognosis. While the relationship ...
    • Ataxia Telangiectasia Mutated Protein Loss and Benefit From Oxaliplatin-based Chemotherapy in Colorectal Cancer. 

      Sundar, R; Miranda, S; Rodrigues, DN; Chénard-Poirier, M; Dolling, D; Clarke, M; Figueiredo, I; Bertan, C; Yuan, W; Ferreira, A; Chistova, R; Boysen, G; Perez, DR; Tunariu, N; Mateo, J; Wotherspoon, A; Chau, I; Cunningham, D; Valeri, N; Carreira, S; de Bono, J (2018-12)
      BACKGROUND: Loss of ataxia telangiectasia mutated (ATM), a key protein regulating DNA repair signaling, has been suggested to increase sensitivity to DNA damaging agents. We conducted a study analyzing the loss of ATM ...
    • Baseline results from the UK SIGNIFY study: a whole-body MRI screening study in TP53 mutation carriers and matched controls. 

      Saya, S; Killick, E; Thomas, S; Taylor, N; Bancroft, EK; Rothwell, J; Benafif, S; Dias, A; Mikropoulos, C; Pope, J; Chamberlain, A; Gunapala, R; SIGNIFY Study Steering Committee; Izatt, L; Side, L; Walker, L; Tomkins, S; Cook, J; Barwell, J; Wiles, V; Limb, L; Eccles, D; Leach, MO; Shanley, S; Gilbert, FJ; Hanson, H; Gallagher, D; Rajashanker, B; Whitehouse, RW; Koh, D-M; Sohaib, SA; Evans, DG; Eeles, RA (2017-07)
      In the United Kingdom, current screening guidelines for TP53 germline mutation carriers solely recommends annual breast MRI, despite the wide spectrum of malignancies typically seen in this group. This study sought to ...
    • Baseline Surveillance in Li-Fraumeni Syndrome Using Whole-Body Magnetic Resonance Imaging: A Meta-analysis. 

      Ballinger, ML; Best, A; Mai, PL; Khincha, PP; Loud, JT; Peters, JA; Achatz, MI; Chojniak, R; Balieiro da Costa, A; Santiago, KM; Garber, J; O'Neill, AF; Eeles, RA; Evans, DG; Bleiker, E; Sonke, GS; Ruijs, M; Loo, C; Schiffman, J; Naumer, A; Kohlmann, W; Strong, LC; Bojadzieva, J; Malkin, D; Rednam, SP; Stoffel, EM; Koeppe, E; Weitzel, JN; Slavin, TP; Nehoray, B; Robson, M; Walsh, M; Manelli, L; Villani, A; Thomas, DM; Savage, SA (2017-12-01)
      Importance: Guidelines for clinical management in Li-Fraumeni syndrome, a multiple-organ cancer predisposition condition, are limited. Whole-body magnetic resonance imaging (WBMRI) may play a role in surveillance of this ...
    • Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial. 

      Ladenstein, R; Pötschger, U; Pearson, ADJ; Brock, P; Luksch, R; Castel, V; Yaniv, I; Papadakis, V; Laureys, G; Malis, J; Balwierz, W; Ruud, E; Kogner, P; Schroeder, H; de Lacerda, AF; Beck-Popovic, M; Bician, P; Garami, M; Trahair, T; Canete, A; Ambros, PF; Holmes, K; Gaze, M; Schreier, G; Garaventa, A; Vassal, G; Michon, J; Valteau-Couanet, D; SIOP Europe Neuroblastoma Group (SIOPEN) (2017-04)
      BACKGROUND: High-dose chemotherapy with haemopoietic stem-cell rescue improves event-free survival in patients with high-risk neuroblastoma; however, which regimen has the greatest patient benefit has not been established. ...
    • Cancer Risks in Patients Treated With Growth Hormone in Childhood: The SAGhE European Cohort Study. 

      Swerdlow, AJ; Cooke, R; Beckers, D; Borgström, B; Butler, G; Carel, J-C; Cianfarani, S; Clayton, P; Coste, J; Deodati, A; Ecosse, E; Gausche, R; Giacomozzi, C; Hokken-Koelega, ACS; Khan, AJ; Kiess, W; Kuehni, CE; Mullis, P-E; Pfaffle, R; Sävendahl, L; Sommer, G; Thomas, M; Tidblad, A; Tollerfield, S; Van Eycken, L; Zandwijken, GRJ (2017-05-01)
      Context: Growth hormone (GH) is prescribed for an increasing range of indications, but there has been concern that it might raise cancer risk. Published data are limited. Objective: To examine cancer risks in relation to ...
    • Candidate genetic modifiers for breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. 

      Peterlongo, P; Chang-Claude, J; Moysich, KB; Rudolph, A; Schmutzler, RK; Simard, J; Soucy, P; Eeles, RA; Easton, DF; Hamann, U; Wilkening, S; Chen, B; Rookus, MA; Schmidt, MK; van der Baan, FH; Spurdle, AB; Walker, LC; Lose, F; Maia, AT; Montagna, M; Matricardi, L; Lubinski, J; Jakubowska, A; Gómez Garcia, EB; Olopade, OI; Nussbaum, RL; Nathanson, KL; Domchek, SM; Rebbeck, TR; Arun, BK; Karlan, BY; Orsulic, S; Lester, J; Chung, WK; Miron, A; Southey, MC; Goldgar, DE; Buys, SS; Janavicius, R; Dorfling, CM; van Rensburg, EJ; Ding, YC; Neuhausen, SL; Hansen, TV; Gerdes, AM; Ejlertsen, B; Jønson, L; Osorio, A; Martínez-Bouzas, C; Benitez, J; Conway, EE; Blazer, KR; Weitzel, JN; Manoukian, S; Peissel, B; Zaffaroni, D; Scuvera, G; Barile, M; Ficarazzi, F; Mariette, F; Fortuzzi, S; Viel, A; Giannini, G; Papi, L; Martayan, A; Tibiletti, MG; Radice, P; Vratimos, A; Fostira, F; Garber, JE; Donaldson, A; Brewer, C; Foo, C; Evans, DG; Frost, D; Eccles, D; Brady, A; Cook, J; Tischkowitz, M; Adlard, J; Barwell, J; Walker, L; Izatt, L; Side, LE; Kennedy, MJ; Rogers, MT; Porteous, ME; Morrison, PJ; Platte, R; Davidson, R; Hodgson, SV; Ellis, S; Cole, T; Godwin, AK; Claes, K; Van Maerken, T; Meindl, A; Gehrig, A; Sutter, C; Engel, C; Niederacher, D; Steinemann, D; Plendl, H; Kast, K; Rhiem, K; Ditsch, N; Arnold, N; Varon-Mateeva, R; Wappenschmidt, B; Wang-Gohrke, S; Bressac-de Paillerets, B; Buecher, B; Delnatte, C; Houdayer, C; Stoppa-Lyonnet, D; Damiola, F; Coupier, I; Barjhoux, L; Venat-Bouvet, L; Golmard, L; Boutry-Kryza, N; Sinilnikova, OM; Caron, O; Pujol, P; Mazoyer, S; Belotti, M; Piedmonte, M; Friedlander, ML; Rodriguez, GC; Copeland, LJ; de la Hoya, M; Segura, PP; Nevanlinna, H; Aittomäki, K; van Os, TA; Meijers-Heijboer, HE; van der Hout, AH; Vreeswijk, MP; Hoogerbrugge, N; Ausems, MG; van Doorn, HC; Collée, JM; Olah, E; Diez, O; Blanco, I; Lazaro, C; Brunet, J; Feliubadalo, L; Cybulski, C; Gronwald, J; Durda, K; Jaworska-Bieniek, K; Sukiennicki, G; Arason, A; Chiquette, J; Teixeira, MR; Olswold, C; Couch, FJ; Lindor, NM; Wang, X; Szabo, CI; Offit, K; Corines, M; Jacobs, L; Robson, ME; Zhang, L; Joseph, V; Joseph, V; Berger, A; Singer, CF; Rappaport, C; Kaulich, DG; Pfeiler, G; Tea, MK; Phelan, CM; Greene, MH; Mai, PL; Rennert, G; Mulligan, AM; Glendon, G; Tchatchou, S; Andrulis, IL; Toland, AE; Bojesen, A; Pedersen, IS; Thomassen, M; Jensen, UB; Laitman, Y; Rantala, J; von Wachenfeldt, A; Ehrencrona, H; Askmalm, MS; Borg, Å; Kuchenbaecker, KB; McGuffog, L; Barrowdale, D; Healey, S; Lee, A; Pharoah, PD; Chenevix-Trench, G; Antoniou, AC; Friedman, E (2015-01)
      BRCA1 and BRCA2 mutation carriers are at substantially increased risk for developing breast and ovarian cancer. The incomplete penetrance coupled with the variable age at diagnosis in carriers of the same mutation suggests ...
    • CD25 Blockade Delays Regulatory T Cell Reconstitution and Does Not Prevent Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation. 

      Locke, FL; Pidala, J; Storer, B; Martin, PJ; Pulsipher, MA; Chauncey, TR; Jacobsen, N; Kröger, N; Walker, I; Light, S; Shaw, BE; Beato, F; Laport, GG; Nademanee, A; Keating, A; Socie, G; Anasetti, C (2017-03)
      Daclizumab, a humanized monoclonal antibody, binds CD25 and blocks formation of the IL-2 receptor on T cells. A study of daclizumab as acute graft-versus-host disease (GVHD) prophylaxis after unrelated bone marrow ...
    • Chemotherapy with radiotherapy influences time-to-development of radiation-induced sarcomas: a multicenter study. 

      Zhang, AY; Judson, I; Benson, C; Wunder, JS; Ray-Coquard, I; Grimer, RJ; Quek, R; Wong, E; Miah, AB; Ferguson, PC; Dufresne, A; Teh, JYH; Stockler, M; Tattersall, MHN (2017-07-25)
      BACKGROUND: An increasing number and proportion of cancer patients with apparently localised disease are treated with chemotherapy and radiation therapy in contemporary oncology practice. In a pilot study of radiation-induced ...
    • Clinical characteristics and treatment outcome in a large multicentre observational cohort of PDGFRA exon 18 mutated gastrointestinal stromal tumour patients. 

      Farag, S; Somaiah, N; Choi, H; Heeres, B; Wang, W-L; van Boven, H; Nederlof, P; Benjamin, R; van der Graaf, W; Grunhagen, D; Boonstra, PA; Reyners, AKL; Gelderblom, H; Steeghs, N (2017-05)
      PURPOSE: Patients, platelet-derived growth factor receptor alpha (PDGFRA) D842V-mutated gastrointestinal stromal tumours (GISTs) are known for their insensitivity to imatinib. However, in clinical practice responses have ...
    • Clinical outcomes of adolescents and young adults with advanced solid tumours participating in phase I trials. 

      Sundar, R; McVeigh, T; Dolling, D; Petruckevitch, A; Diamantis, N; Ang, JE; Chenard-Poiriér, M; Collins, D; Lim, J; Ameratunga, M; Khan, K; Kaye, SB; Banerji, U; Lopez, J; George, AJ; de Bono, JS; van der Graaf, WT (2018-09)
      BACKGROUND: Adolescent and young adult (AYA) patients with advanced solid tumours are often considered for phase I clinical trials with novel agents. The outcome of AYAs in these trials have not been described before. AIM: ...
    • Clinical, Radiologic, Pathologic, and Molecular Characteristics of Long-Term Survivors of Diffuse Intrinsic Pontine Glioma (DIPG): A Collaborative Report From the International and European Society for Pediatric Oncology DIPG Registries. 

      Hoffman, LM; Veldhuijzen van Zanten, SEM; Colditz, N; Baugh, J; Chaney, B; Hoffmann, M; Lane, A; Fuller, C; Miles, L; Hawkins, C; Bartels, U; Bouffet, E; Goldman, S; Leary, S; Foreman, NK; Packer, R; Warren, KE; Broniscer, A; Kieran, MW; Minturn, J; Comito, M; Broxson, E; Shih, C-S; Khatua, S; Chintagumpala, M; Carret, AS; Escorza, NY; Hassall, T; Ziegler, DS; Gottardo, N; Dholaria, H; Doughman, R; Benesch, M; Drissi, R; Nazarian, J; Jabado, N; Boddaert, N; Varlet, P; Giraud, G; Castel, D; Puget, S; Jones, C; Hulleman, E; Modena, P; Giagnacovo, M; Antonelli, M; Pietsch, T; Gielen, GH; Jones, DTW; Sturm, D; Pfister, SM; Gerber, NU; Grotzer, MA; Pfaff, E; von Bueren, AO; Hargrave, D; Solanki, GA; Jadrijevic Cvrlje, F; Kaspers, GJL; Vandertop, WP; Grill, J; Bailey, S; Biassoni, V; Massimino, M; Calmon, R; Sanchez, E; Bison, B; Warmuth-Metz, M; Leach, J; Jones, B; van Vuurden, DG; Kramm, CM; Fouladi, M (2018-07-01)
      Purpose Diffuse intrinsic pontine glioma (DIPG) is a brainstem malignancy with a median survival of < 1 year. The International and European Society for Pediatric Oncology DIPG Registries collaborated to compare clinical, ...